Valneva/Emergent BioSolutions’ Candidate Zika Vaccine Shows Early Clinical Promise
A European/US company collaboration has reported encouraging safety and immunogenicity in early clinical studies with an alum-adjuvanted Zika vaccine based on inactivated whole virus.
Overcome The Challenges Of An Ultra-Rare Disease Trial
ArQule is a personalized medicine company working in the oncology space to develop treatments that target specific mutations. The Massachusetts-based company faces many challenges in this space, including one that is common to many cancer treatments.
Phase I Gives Hope for First Zika Vaccine
Results from a Phase I trial showed promising safety and efficacy of a potential first vaccine against the mosquito-borne Zika virus, developed by French biotech Valneva and US biopharma Emergent BioSolutions.
SQZ Biotech pushes forward with its method to squeeze drugs into cells
One Watertown, Mass.-based biotech is working to capitalize on growing momentum for cell and gene therapies — and it seems to have found its opening. The company is working on a technology that will squeeze cells to open up tiny pores in their membranes to deliver gene therapies or medicines straight into the cell. And SQZ has had a busy fall.
Oxurion’s CEO Dr. Patrik De Haes discusses three pipeline candidates for diabetic eye disease
Patrik De Haes, MD, CEO of Oxurion, discusses the company’s three disease-modifying drug candidates for the treatment of diabetic eye disease with EyeWire News at the Ophthalmology Innovation Summit in Chicago.
Arena bags big deal with United for PAH drug ralinepag
Arena’s run of positive news continues, with a massive $800 million upfront licensing deal with United Therapeutics for its pulmonary arterial hypertension drug ralinepag. The global deal, which also includes $400 million in milestones and double-digit royalties, comes on the heels of well-regarded phase 2 data with the oral prostacyclin receptor agonist in PAH that caused Arena’s shares to soar when it was released last year.
Could Pot Help Solve The Opioid Crisis?
A $238,000 federal study will follow more than 10,000 medical marijuana patients in New York over the next two years to see if their opioid use drops. Scott Jordan never thought weed would help him kick the painkillers he took for a bad back. “I smoked pot in high school,” he told BuzzFeed News. “I didn’t really believe medical marijuana was going to help me.”
Arena Pharma soars on deal with United Therapeutics for hypertension drug
Shares of Arena Pharmaceuticals Inc jumped nearly 30 percent after the drug developer sold rights to develop and sell its hypertension treatment to United Therapeutics Corp, fetching it $800 million in an upfront payment. Arena Pharma said the money will help it prepare for the eventual launch of its bowel disorder drugs.
